Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

EZVIZ unveils its groundbreaking H9c Dual-lens Smart Pan-and-tilt Camera series: a new paradigm for automated, all-round outdoor protection

Published

on

ezviz-unveils-its-groundbreaking-h9c-dual-lens-smart-pan-and-tilt-camera-series:-a-new-paradigm-for-automated,-all-round-outdoor-protection

By combining a pan-and-tilt panoramic lens and a fixed 180-degree wide-angle lens, one H9c Dual smartly secures large areas with performance better than that of two ordinary ones.
HOOFDDORP, Netherlands, May 6, 2024 /PRNewswire/ — EZVIZ, a leading global player in innovative smart home security, proudly introduces the H9c Dual series, its latest dual-lens outdoor pan-and-tilt cameras that redefine smart protection for homes and small businesses. With options in 2K and 3K resolutions, their groundbreaking design combines a sharp bullet camera and a flexible PT camera, addressing complex security needs effectively. The interlinked dual lenses work collaboratively to safeguard wide property areas, detect and track activities, and offer auto-patrol options for hands-free security.

“The H9c Dual challenges traditional outdoor cameras with unrivaled vision, unmatched automation, and high versatility for basically any scenario,” said Candice Tu, the lead product manager, “EZVIZ leads the way in the development and application of advanced dual-lens technology. This underlines our dedication to bringing cutting-edge technology within reach for practical, everyday situations.”
At the core of the H9c Dual is its groundbreaking dual-lens technology, highlighted by EZVIZ’s distinctive co-action function. The two lenses can work independently at two static viewing angles or act together as a team. When the fixed lens detects motions, the pan-and-tilt lens automatically rotates to track the same activity. This co-action function can also be manually controlled through the EZVIZ App.
The series addresses unnoticed blind spots by offering a 180-degree comprehensive view in a single frame, supplemented by the bottom PT lens for intricate close-ups. Both lenses, with high resolutions of 2K/3K, use built-in AI chips to detect people and vehicles in customizable zones, ensuring users are informed of crucial activities. Users can set up to four patrol spots for the PT lens to complete automatic rotations on a schedule.
Equipped with powerful LEDs, the H9c Dual provides color night vision up to 40 meters and warns potential trespassers with a loud siren and dazzling flashlight upon detection. Offering superior protection compared to a traditional two-camera system, the H9c is a breeze to set up thanks to its adaptable mounting design. Users can manage and control their H9c through the user-friendly EZVIZ App, and enjoy seamless integration with prevailing voice assistants and the larger EZVIZ ecosystem.
Learn more at www.ezviz.com.
Photo – https://mma.prnewswire.com/media/2404810/EZVIZ_H9c_Dual_Lens_Pan_Tilt_Wi_Fi_Camera.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ezviz-unveils-its-groundbreaking-h9c-dual-lens-smart-pan-and-tilt-camera-series-a-new-paradigm-for-automated-all-round-outdoor-protection-302136133.html

Continue Reading
Advertisement
Stake.com

Artificial Intelligence

ActiveOps becomes Official Analytics Partner to Great Britain 7s Rugby team

Published

on

activeops-becomes-official-analytics-partner-to-great-britain-7s-rugby-team

Highlighting the necessity of data-driven decision-making as a central tenet to both athletes on the pitch and employees in the workforceAgreement enables ActiveOps to provide analytics expertise to support the teams growth and performance plans globallyGlobal deal covers both Men and Women’s GB7s teams for the 2024/25 HSBC SVNS SeasonLONDON, May 30, 2024 /PRNewswire/ — ActiveOps, leaders in providing AI-powered Decision Intelligence software for service operations, is extremely proud to announce a strategic and global partnership with Great Britain men’s & women’s rugby Sevens. (GB7s), ActiveOps will serve as the Official Analytics Partner for GB7s for the remainder of the 2023-2024 season including the tournaments leading up to the 2024 Paris Olympics and all of 2024-2025 season across eight locations worldwide.

 
The SaaS company, with Decision Intelligence at its core, will provide invaluable support to enhance the team’s performance, outreach and overall presence in the global sports community.
“We are delighted to welcome ActiveOps as a partner to GB7s,” said Joe Lydon, Performance Director at GB7s. “ActiveOps’ commitment to delivering operational excellence based on data-driven decision intelligence aligns seamlessly with our dedication to achieving success on and off the rugby field. This represents a powerful partnership that will help us create and better support a Data Pathway for future GB7s rugby talent and undoubtedly elevate our teams to new heights.”
Richard Jeffery. Chief Executive Officer, ActiveOps, added: “We are thrilled to announce our partnership with GB7s. We are joining forces with a team that embodies the values of excellence, teamwork, and dedication. The synergies with ActiveOps are clear given that GB7s bases its own team performances on extensive sports analytics which provides the teams with valuable information to make data-driven decisions to improve performance.”
For more information, visit www.activeops.com/gb7
Notes to editors
About HSBC SVNS
The SVNS, known as the HSBC SVNS for sponsorship reasons, is an annual series of international rugby sevens tournaments run by World Rugby featuring national sevens teams. Organised for the first time in the 1999–2000 season as the IRB World Sevens Series, the competition was formed to promote an elite-level of international rugby sevens and develop the game into a viable commercial product. The competition has been sponsored by banking group HSBC since 2014.
About GB Rugby SVNS
The Great Britain men’s and women’s national rugby sevens team are the international rugby 7s team that is the representative team of Great Britain. The team competes in the annual World Rugby Sevens Series as well as the Olympic Games and European Games. Historically, Great Britain was represented in rugby 7s by England, Scotland and Wales but the inclusion of Rugby 7s at the Olympic and European Games, together with funding issues has resulted in the formation of a permanent combined team from 2023.
About ActiveOps
At ActiveOps, we believe the ability to make every decision – the right decision, at the right time, will transform operations. Our blend of AI and human intelligence delivers the most complete and useful set of predictive and prescriptive insight to help service operations make better decisions – faster.
Service Operations has been in our DNA for 20 years. Our AI-powered SaaS solutions are underpinned by 15+ years of operational data and our AOM methodology that’s proven to drive cross department decision-making. We call this Decision Intelligence for Service Operations – and we are dedicated to the needs of banking, insurance, BPS and healthcare organisations, globally.
To find out more, visit www.activeops.com
Photo – https://mma.prnewswire.com/media/2426026/ActiveOps_1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/activeops-becomes-official-analytics-partner-to-great-britain-7s-rugby-team-302159479.html

Continue Reading

Artificial Intelligence

The Lancet Publishes Results from World’s Largest Coronary CT Registry Showing New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation At Least 10 Years in Advance

Published

on

the-lancet-publishes-results-from-world’s-largest-coronary-ct-registry-showing-new-ai-technology-can-predict-cardiac-events-due-to-coronary-inflammation-at-least-10-years-in-advance

OXFORD, England, May 30, 2024 /PRNewswire/ — Caristo Diagnostics Limited, a global leader in cardiovascular disease diagnostics and risk prediction, announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo’s CaRi-Heart® AI technology to quantify coronary artery inflammation and accurately predict cardiac events.

This landmark study, titled “Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study,” analysed results from the first 40,000 patients enrolled in the “ORFAN” registry, the world’s largest study that evaluates coronary computed tomography angiography (CCTA) imaging biomarkers in predicting long-term cardiovascular outcomes.
Key study findings include:
Among patients undergoing CCTA, more than 80% did not have obstructive coronary artery disease (CAD) at the time of imaging, but twice as many fatal and non-fatal cardiac events occurred in that groupCoronary inflammation, as measured by Caristo’s CaRi-Heart FAI-ScoreTM, predicted fatal and non-fatal cardiac events (including heart attack and new heart failure), independently from traditional risk factors, routine clinical CCTA interpretation, calcium scoring and plaque quantification, at least 10 years in advanceEven among the 50% of patients who had no or minimal coronary plaque at the time of the initial CCTA, those with the most abnormal FAI-Score results experienced a 9.5-fold higher risk for cardiac mortality and 5.5-fold higher risk for major adverse cardiac events (MACE)Caristo’s AI-Risk model, CaRi-Heart Risk Score, outperformed other scores in routine clinical use for prediction of cardiac mortality, and when presented to clinicians, resulted in changes of management decision in 45% of the patients. Most changes were due to clinicians’ decision to target the previously undetected coronary inflammation.”The ORFAN study is an expanding global registry which will include long-term clinical and outcome data for 250,000 patients from around the world, and we are very pleased to publish these initial results,” said Keith Channon, MD, Professor of Cardiovascular Medicine at the University of Oxford, Caristo’s Chief Medical Officer, and co-author of The Lancet publication. “Coronary inflammation is a crucial piece of the puzzle in predicting heart attack risk. We are excited to discover that CaRi-Heart results performed exceptionally well in predicting patient cardiac events. This tool is well positioned to help clinicians identify high-risk patients with seemingly ‘normal’ CCTA scans.”
Ron Blankstein, MD, Professor of Medicine and Radiology at Harvard Medical School, Director of Cardiac Computed Tomography at Brigham and Women’s Hospital, and co-author of the publication, commented: “This study, which represents one of the largest studies in the field of CCTA, has important implications for the field of preventive cardiology. I am excited about the potential of the FAI-Score biomarker, which has promising prognostic value beyond existing CT-based methods such as plaque, calcium scoring, and CAD-RADS based interpretation.”  
The study underlines the need for a robust risk prediction tool that can identify vulnerable patients with inflamed coronary arteries, particularly in those without obstructive CAD. This approach would transform CCTA from a test used to triage a minority of patients for further intervention into a prevention tool that guides management for all patients undergoing CCTA.
SCCT Webinar to Feature Study Co-Authors on June 27:
On June 27 at 11am EDT, the Society of Cardiovascular Computed Tomography (SCCT) will host a webinar on The Lancet publication findings to be presented by the lead author, Prof. Charalambos Antoniades, and joined by several co-authors (Prof. Channon, Prof. Stefan Neubauer, Prof. Ed Nicol, Prof. Blankstein and Prof. Milind Desai). The webinar will present the key results from The Lancet publication along with a panel discussion on the implications of this landmark study. Check www.caristo.com in early June for the webinar registration link.
Caristo’s patented CaRi-Heart technology marks a scientific breakthrough that is radically transforming the traditional approach to heart disease prediction, prevention and management. The technology applies advanced AI algorithms to routine coronary computed tomography angiography (CCTA) scans to visualize and quantify coronary inflammation, the otherwise invisible disease mechanism responsible for many fatal heart attacks and strokes. Prior to this publication by The Lancet, earlier validation results showing CaRi-Heart technology’s ability to aid the prediction of heart attacks were published in leading medical journals including the Lancet, JACC, European Heart Journal, and Cardiovascular Research.
The CaRi-Heart® technology is in clinical use in the UK, European Union, and Australia.
About Caristo Diagnostics Limited
Caristo Diagnostics is a global leader in cardiac and vascular disease diagnostics and risk prediction. Founded in 2018 as a spin-out company from the University of Oxford, the world’s #1 research university, Caristo has developed a portfolio of imaging-based and AI-assisted platforms that can be applied to aid the prediction and diagnosis of heart attack, stroke, and diabetes. Caristo has been recognized by Newsweek as one of the best digital health companies, and highlighted by Nature as one of the most exciting science-based companies to have emerged from academic labs. Find Caristo online on its website, LinkedIn and X.
Logo: https://mma.prnewswire.com/media/2054669/4734272/Caristo_Logo.jpg
ContactFrank Cheng, Caristo Diagnostics [email protected]

View original content:https://www.prnewswire.co.uk/news-releases/the-lancet-publishes-results-from-worlds-largest-coronary-ct-registry-showing-new-ai-technology-can-predict-cardiac-events-due-to-coronary-inflammation-at-least-10-years-in-advance-302159435.html

Continue Reading

Artificial Intelligence

ZEISS announces OCT technology enhancements to better support growing era of data-driven patient care

Published

on

zeiss-announces-oct-technology-enhancements-to-better-support-growing-era-of-data-driven-patient-care

ZEISS Medical Ecosystem fortifies the CIRRUS 6000 with the U.S. market’s largest OCT reference database and advanced cybersecurity features.
DUBLIN, Calif., May 30, 2024 /PRNewswire/ — ZEISS Medical Technology announced today that the CIRRUS® 6000 from ZEISS now enables a highly efficient and data-driven workflow for ophthalmologists, supported by the largest OCT (optical coherence tomography) reference database in the U.S. market, as well as newly enhanced cybersecurity features. As part of the ZEISS Medical Ecosystem, the latest OCT device from ZEISS, which recently received clearance by the U.S. Food and Drug Administration (FDA), helps support informed, data-driven patient care decisions across ophthalmic workflows from disease diagnosis to treatment and ongoing management.

Proven Analytics: As the largest reference database across all OCT devices in the U.S. market today, the ZEISS CIRRUS 6000 reference database now offers a comprehensive library of 870 healthy eyes, more than tripling the previous versions, with greater diversity, taking into account different optic disc sizes in addition to age. Elevating the standard of care for patients, the expanded reference database is a useful tool to facilitate individualized approaches to diagnoses and ocular health and disease management.
“ZEISS continues to forge the way toward a future of more personalized care by pioneering state-of-the-art digital workflow innovations that are proven to increase efficiencies and improve patient outcomes,” 1 says Euan S. Thomson, Ph.D., President of Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology. “Our expansive CIRRUS 6000 reference database provides greater data-driven insights to ophthalmologists.”
Performance: The ZEISS CIRRUS 6000 OCT provides high-speed imaging with high-definition detail, a wider field of view, enhanced visualization with AngioPlex® OCT Angiography, and clinically validated applications for retina, glaucoma, and anterior segment – all supporting more insights into a patient’s condition in less time with improved security to meet clinical compliance needs.
Patient-First Design: The CIRRUS 6000 offers enhanced security and seamless transfer of patient data from previous generations of CIRRUS for continuity of patient care. Designed to meet evolving clinical compliance and security needs, new cybersecurity features protect against cyber threats, offer advanced data security and instant disaster recovery, provide enhanced password security, enterprise-scale security requirements, and more.
”ZEISS is highly committed to improving patient care and is proud to enhance the CIRRUS OCT brand with digital tools that help keep clinics efficient and compliant. The CIRRUS 6000 enables optimized, data-driven diagnoses and empowers clinicians to manage complex ophthalmic conditions with confidence,” says Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology.
Learn more about the enhanced CIRRUS® 6000 from ZEISS at www.zeiss.com/cirrus6000.
1 https://www.dovepress.com/getfile.php?fileID=95911
Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: [email protected]
Contact for the pressFrank SmithHead of Global Communications Ophthalmic DevicesCarl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: [email protected]
www.zeiss.com/newsroom
Brief Profile
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med
Photo – https://mma.prnewswire.com/media/2425218/ZEISS_CIRRUS_6000_OCT.jpgLogo – https://mma.prnewswire.com/media/546786/ZEISS_v1_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/zeiss-announces-oct-technology-enhancements-to-better-support-growing-era-of-data-driven-patient-care-302158900.html

Continue Reading

Trending